Research Article

New Insights into the Association between Fibrinogen and Coronary Atherosclerotic Plaque Vulnerability: An Intravascular Optical Coherence Tomography Study

Jun Wang, Lu Jia, Xing Li, Siyu Jin, Xiaomei Li, Fen Liu, Chunfang Shan, Yu Zhang, and Yining Yang

Department of Coronary Heart Disease, the First Affiliated Hospital of Xinjiang Medical University, Urumqi 830011, China

Correspondence should be addressed to Yining Yang; yangyn5126@163.com

Received 25 November 2018; Revised 31 January 2019; Accepted 24 February 2019; Published 2 April 2019

Academic Editor: Giuseppe Biondi-Zoccai

Copyright © 2019 Jun Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Fibrinogen levels have been associated with coronary plaque vulnerability in experimental studies. However, it has yet to be determined if serum fibrinogen levels are independently associated with coronary plaque vulnerability as detected by optical coherence tomography (OCT) in patients with coronary heart disease. Methods. Patients with coronary heart disease (CHD) who underwent coronary angiography and OCT in our department from January 2015 to August 2018 were included in this study. Coronary lesions were categorized as ruptured plaque, nonruptured with thin-cap fibroatheroma (TCFA), and nonruptured and non-TCFA. Presence of ruptured plaque and nonruptured with TCFA was considered to be vulnerable lesions. Determinants of coronary vulnerability were evaluated by multivariable logistic regression analyses. Results. A total of 154 patients were included in this study; 17 patients had ruptured plaques, 15 had nonruptured plaques with TCFA, and 122 had nonruptured plaques with non-TCFA. Results of univariate analyses showed that being male, diabetes, current smoking, high body mass index (BMI), and clinical diagnosis of acute coronary syndrome (ACS) were associated with coronary vulnerability. No significant differences were detected in patient characteristics, coronary angiographic findings, and OCT results between patients with higher and normal fibrinogen. Results of multivariate logistic analyses showed that diabetes and ACS were associated with TCFA, while diabetes, higher BMI, and ACS were associated with plaque rupture. Conclusions. Diabetes, higher BMI, and ACS are independently associated with coronary vulnerability as detected by OCT. Serum fibrinogen was not associated with coronary vulnerability in our cohort.

1. Introduction

Conventional cardiovascular risk factors, such as smoking, diabetes, hypertension, and dyslipidemia, have been associated with incidence of acute cardiovascular adverse events in patients with coronary heart disease (CHD) [1]. However, acute coronary events can occur in patients without conventional cardiovascular risk factors, indicating the presence of unknown risk factors [1, 2]. Pathologically, incidences of acute coronary events have been related to coronary lesion vulnerability [3]. Therefore, identifying novel factors associated with coronary plaque vulnerability may be important for predicting acute coronary events in CHD patients. Accumulating evidence suggests that plasma fibrinogen, an active factor involved in coagulation, may contribute to the risk of acute thrombotic disease via its proinflammatory effects [4]. Elevated fibrinogen levels have been observed in patients who are at higher risk for CHD, such as those who smoke and have diabetes, hypertension, obesity, lipid metabolism disorders, menopause, and depression [5, 6]. In contrast, factors that reduce CHD risk, such as regular exercise, also reduce fibrinogen levels [7, 8]. Experimental studies have also suggested that fibrinogen and fibrin degradation products may increase coronary plaque vulnerability by stimulating coagulation, platelet aggregation, and vascular endothelial dysfunction [9]. Clinical studies have also demonstrated that fibrinogen is correlated with atherosclerosis severity, as determined by both coronary angiography (CAG) and carotid ultrasonography [10, 11]. However, whether plasma fibrinogen is independently associated with coronary lesion vulnerability in CHD patients remains to be determined.
Optical coherence tomography (OCT) is an emerging tool used to evaluate coronary plaque vulnerability in vivo. OCT can provide intraluminal evidence that confers more accurate findings of plaque characteristics compared to intravascular ultrasound (IVUS) imaging [12]. Although the association between fibrinogen and in vivo coronary plaque characteristics has only been examined using IVUS [13, 14], the literature does not provide any evidence that plasma fibrinogen is independently associated with coronary lesion vulnerability as detected by OCT. The aim of the current study was to evaluate the potential association between fibrinogen and coronary vulnerability using OCT.

2. Methods

2.1. Patient Population. Patients with CHD who were scheduled to receive coronary angiography and OCT in our department from January 2015 to August 2018 were included in this study. Patients with either stable coronary artery disease (SAP) or non-ST-elevation acute coronary syndrome NSTE-ACS were eligible for study inclusion. Diagnosis was in accordance with previously established guidelines [15]. The flow chart for patient inclusion and exclusion is shown in Figure 1. Patients with the following clinical conditions were excluded, as these factors may affect fibrinogen plasma levels: decreased white blood cell counts, decreased platelet counts, hepatic or renal dysfunction, inflammatory disease, prolonged occluded coronary bypass graft, malignant tumors, and other diseases that may cause fibrinogen elevation. Written informed consent for CAG and OCT were obtained from all patients. The study protocol was approved by the local ethics committee.

2.2. Definition of Cardiovascular Risk Factors. Hypertension was defined as elevated blood pressure, including systolic blood pressure (SBP) > 140 mmHg or diastolic blood pressure (DBP) > 90 mmHg. Patients with a reported history of hypertension and who had used any antihypertensive medications were also considered hypertensive [16]. Dyslipidemia was defined using current guidelines [17]: low-density lipoprotein cholesterol (LDL-C) > 3.1 mmol/L, triglyceride (TG) > 2.3 mmol/L, high-density lipoprotein cholesterol (HDL-C) < 1.0 mmol/L, and total cholesterol (TC) > 5.2 mmol/L. A lipoprotein (a) (Lp(a)) > 300 mg/L has also been listed as a risk factor for cardiovascular diseases [18, 19]. Body mass index (BMI) was determined by ratio of body weight (kg) to height (m²). A BMI > 28 kg/m² was considered obesity, and BMI between 24 – 28 kg/m² was considered overweight [20]. Diabetes mellitus (DM) was diagnosed when glucose > 126 mg/dL or glycated hemoglobin (HbA1c) was > 6.5%, in the presence of active treatment with insulin or oral antidiabetic agents, in accordance with the American Diabetes Association criteria [21].

2.3. Blood Tests. Blood samples were collected from patients in the fasting state. Serum samples were separated by
analyses were performed using SPSS Software. Multivariate logistic regression analyses. Atwo-sided significance in univariate analysis were included in the TCFA (Model 2). The parameters that showed statistical the independent predictors of plaque rupture (Model 1) and ACS were independently associated with plaque rupture, while diabetes and ACS were independently associated with plaque rupture and TCFA (Table 3).

3.4. Relationship of Fibrinogen Level with Patient Characteristics and OCT Findings. Fibrinogen levels according to different conventional CHD risk factors, biochemical parameters, and concurrent medications are shown in Table 4. Plasma fibrinogen levels were not significantly affected by the above factors. Moreover, no statistical difference was detected for CAG and OCT findings between patients with normal or higher fibrinogen levels (Table 5).
Figure 3: Continued.
4. Discussion

In this study, we found that plasma fibrinogen levels were not associated with coronary lesion vulnerability as determined using OCT. Moreover, diabetes and ACS were independently associated with coronary lesion vulnerability, as determined by TCFA and plaque rupture in OCT. Similarly, diabetes, ACS, and obesity were independent determinants of plaque rupture in OCT. These findings contrasted the previous hypothesis that higher plasma fibrinogen levels may be a marker or risk factor for coronary lesion vulnerability.

4.1. Fibrinogen and Coronary Atherosclerotic Plaque Vulnerability. Plaque rupture and TCFA have been established as manifestations of plaque vulnerability in OCT studies [22]. Both plaque rupture and TCFA are key pathophysiologic features of ACS. However, previous studies suggested that plasma fibrinogen may accelerate the process of plaque rupture via its proinflammatory [25] and prothrombotic [26] effects. Thus, it was proposed that increased plasma fibrinogen levels in CAD patients may serve as a biomarker for atherosclerosis burden [27]. Our study, using the current gold-standard tool to evaluate coronary vulnerability, indicated that fibrinogen levels were not independently associated with OCT-derived features of coronary vulnerability, including plaque rupture and TCFA development. However, antiplatelet therapy and statins can influence the detection of vulnerable plaques [28, 29]. In our study, medications were not statistically different among the three groups. These results suggest that the potential association between fibrinogen levels and coronary vulnerability raised in previous studies may be confounded by other CHD risk factors. This is inconsistent with previous studies that showed that fibrinogen was independently associated with coronary severity in CHD patients [30]. Of note, CAG, rather than intraluminal tools, was used to evaluate coronary lesion severity. Interestingly, another study using IVUS showed that fibrinogen levels correlated with plaque progression [13]. However, only 60 patients were included in that study. Similarly, another study using VH-IVUS concluded that fibrinogen degradation products are associated with larger plaques that have a larger necrotic core [14], but this finding was not confirmed by a subsequent large study that also used histology-IVUS. This study also did not confirm a relationship between fibrinogen and TCFA [31]. One explanation for the inconsistent findings is that genetic factors, such as polymorphisms in fibrinogen loci raised by a multiethnic meta-analysis [32], may confound the association between fibrinogen and coronary vulnerability. However, results of our study provide a more accurate association, since OCT yields higher resolution compared to IVUS to evaluate intraluminal lesions in the coronary artery [33]. Although experimental studies have demonstrated multiple mechanisms underlying the potential role of fibrinogen for accelerating coronary
|                         | Ruptured plaque group | Nonrupture with TCFA group | Nonrupture and non-TCFA group | U/χ²   | P     |
|-------------------------|-----------------------|----------------------------|-------------------------------|--------|-------|
| **Male**                | 15 (88.2)            | 13 (88.7)                  | 74 (60.7)                     | 8.177  | 0.087 |
| **Age**                 | 58.94±10.23          | 59.3±9.60                  | 56.59±12.07                   | 0.448  | 0.640 |
| **Hypertension**        | 10 (58.8)            | 9 (60.0)                   | 62 (50.8)                     | 0.549  | 0.688 |
| **Diabetes mellitus**   | 10 (58.8)            | 9 (60.0)                   | 62 (50.8)                     | 0.573  | <0.001|
| **Current smoking**     | 11 (64.7)            | 9 (60.0)                   | 46 (37.7)                     | 6.436  | 0.040 |
| **Current drinking**    | 4 (23.5)             | 1 (6.7)                    | 26 (21.3)                     | 3.733  | 0.305 |
| **Family history**      | 2 (11.8)             | 1 (6.7)                    | 26 (21.3)                     | 2.931  | 0.231 |
| **BMI**                 | 29.09±3.88           | 26.64±2.45                 | 24.60±2.98                    | 178.47 | <0.001|
| **LDL-c (mmol/l)**      | 3.90±0.87            | 2.48±0.54                  | 2.36±0.94                     | 0.104  | 0.902 |
| **HDL-c (mmol/l)**      | 1.00±0.20            | 1.00±0.22                  | 1.03±0.27                     | 2.170  | 0.118 |
| **ApoA1 (g/L)**         | 4.08±0.54            | 4.08±0.54                  | 4.08±0.52                     | 0.033  | 0.968 |
| **ApoB (g/L)**          | 3.61±0.98            | 3.96±0.66                  | 3.74±1.23                     | 0.340  | 0.712 |
| **Lp(a) (g/L)**         | 2.08±1.02            | 2.26±1.33                  | 1.94±1.61                     | 0.299  | 0.742 |
| **TBil (mmol/l)**       | 27.22±17.78          | 191.92±76.26               | 256.05±234.49                 | 0.641  | 0.543 |
| **HbA1c (%)**           | 7.07±1.34            | 6.80±1.03                  | 6.32±1.28                     | 1.802  | 0.172 |
| **Uric acid (mmol/L)**  | 348.79±76.98         | 341.39±80.28               | 335.41±98.44                  | 0.163  | 0.850 |
| **Creatinine (mmol/L)** | 76.29±17.46          | 74.58±17.28                | 74.25±18.77                   | 0.091  | 0.913 |
| **Carbamide (mmol/l)**  | 5.95±6.79            | 4.98±1.43                  | 5.56±1.61                     | 1.455  | 0.237 |
| **eGFR**                | 112.59±7.06          | 106.5±31.03                | 107.65±36.96                  | 0.313  | 0.876 |
| **Fibrinogen (g/L)**    | 3.71±0.54            | 3.27±0.40                  | 3.56±1.06                     | 0.840  | 0.434 |
| **FDP (μg/L)**          | 150 (1.2, 3.65)      | 100 (0.88, 1.40)           | 150 (1.00, 2.70)              | 5.249  | 0.027 |
| **TBIL (mmol/l)**       | 11.93±3.89           | 12.89±4.11                 | 13.60±10.11                   | 0.267  | 0.766 |
| **DBIL (mmol/l)**       | 2.88±1.47            | 3.53±1.47                  | 3.74±2.67                     | 0.893  | 0.411 |
| **IBIL (mmol/l)**       | 9.13±3.80            | 9.36±4.00                  | 9.54±5.87                     | 0.043  | 0.958 |
| **PLT (10^9/L)**        | 223.12±51.27         | 237.6±77.93                | 232.33±65.22                  | 0.214  | 0.808 |
| **MPV (fL)**            | 10.31±0.75           | 10.43±1.38                 | 10.75±1.08                    | 1.676  | 0.191 |
| **PCT (%)**             | 0.23±0.05            | 0.24±0.07                  | 0.25±0.06                     | 0.526  | 0.592 |
| **PDW**                 | 13.02±3.96           | 14.28±3.39                 | 14.80±2.76                    | 2.768  | 0.066 |
| **RBC(10^12)/L**        | 4.77±0.46            | 4.8±0.36                   | 4.76±0.49                     | 0.060  | 0.941 |
| **HCT (%)**             | 0.44±0.05            | 0.43±0.04                  | 0.43±0.04                     | 0.277  | 0.758 |
| **HGB (g/L)**           | 144.35±6.82          | 142.87±11.77               | 142.39±15.62                  | 0.123  | 0.885 |
| **Hs-CRP**              | 2.43 (0.82, 3.95)    | 0.86 (0.27, 2.15)          | 1.46 (0.55, 8.32)             | 0.831  | 0.660 |
| **ASCS**                | 13 (76.5)            | 10 (66.7)                  | 39 (32.0)                     | 17.05  | <0.001|
| **Aspirin**             | 11 (64.7)            | 11 (73.3)                  | 91 (74.6)                     | 0.079  | 0.701 |
| **Statins**             | 11 (64.7)            | 13 (86.7)                  | 94 (77.0)                     | 2.194  | 0.334 |
| **β-Blockers**          | 7 (41.2)             | 3 (20.0)                   | 46 (35.7)                     | 2.001  | 0.368 |
| **ACEI/ARB**            | 6 (35.3)             | 6 (40.0)                   | 46 (35.7)                     | 0.076  | 0.963 |
| **CCB**                 | 5 (29.4)             | 5 (33.3)                   | 29 (23.8)                     | 0.782  | 0.676 |
| **Oral hypoglycemic drugs** | 4 (23.5)             | 3 (20.0)                   | 21 (17.2)                     | 0.416  | 0.812 |
| **Insulin**             | 2 (11.8)             | 1 (6.7)                    | 13 (10.7)                     | 0.295  | 0.865 |

Values are presented as n (%), or mean ± SD; BMI, body mass index; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; BPC, blood platelet count; MPV, mean platelet volume; PCT, thrombocytocrit; PDW, platelet distribution width; RBC, red blood cell; PLT, platelet; HCT, hematocrit; HGB, hemoglobin; TBIL, total bilirubin; DBIL, direct bilirubin; IBIL, unconjugated bilirubin; SAP, stable angina pectoris; UAP, unstable angina pectoris; NSTEMI, non-ST-segment elevation myocardial infarction; Apo A1, Apo lipoprotein A1; Apo B, Apo lipoprotein B; Lp (a), Lipoprotein (a); FDP, fibrinogen degeneration products; Hs-CRP, high sensitivity C-reactive protein.
Table 2: Coronary angiographic findings and OCT characteristics according to plaque vulnerability.

|                      | Ruptured plaque group | Nonrupture with TCFA group | Nonrupture and non-TCFA group | $\chi^2$ | P     |
|----------------------|-----------------------|----------------------------|-------------------------------|---------|-------|
| ACS-IFC (%)          |                       |                            |                               |         |       |
| No                   | 15 (88.2)             | 11 (73.3)                  | 108 (88.5)                    | 2.271   | 0.321 |
| Yes                  | 2 (11.8)              | 4 (26.7)                   | 14 (11.5)                     |         |       |
| Vasa vasorum         |                       |                            |                               | 1.826   | 0.401 |
| No                   | 16 (94.1)             | 12 (80.0)                  | 111 (91.0)                    |         |       |
| Yes                  | 1 (5.9)               | 3 (20.0)                   | 11 (9.0)                      |         |       |
| Thrombus             |                       |                            |                               | 31.431  | <0.001|
| No                   | 4 (23.5)              | 10 (66.7)                  | 107 (87.7)                    |         |       |
| Yes                  | 13 (76.5)             | 5 (33.3)                   | 15 (12.3)                     |         |       |
| Macrophage accumulation|                     |                            |                               | 32.148  | <0.001|
| 0                    | 3 (17.6)              | 3 (20.0)                   | 79 (64.8)                     |         |       |
| 1                    | 7 (41.2)              | 7 (46.7)                   | 25 (20.5)                     |         |       |
| 2                    | 5 (29.4)              | 4 (26.7)                   | 18 (14.8)                     |         |       |
| 3                    | 1 (5.9)               | 1 (6.7)                    | 0 (0.0)                       |         |       |
| 4                    | 1 (5.9)               | 0 (0.0)                    | 0 (0.0)                       |         |       |
| MLA (mm$^2$)         | 3.28±1.89             | 3.51±2.08                  | 3.50±1.97                     | 0.090   | 0.914 |
| NLA (mm$^2$)         | 11.60±3.73            | 10.78±3.03                 | 10.19±3.08                    | 1.777   | 0.173 |
| Rate of stenosis     | 81.12±15.89           | 75.67±13.35                | 72.93±17.14                   | 1.870   | 0.158 |
| Calcified nodule     |                       |                            |                               | 1.137   | 0.547 |
| No                   | 17 (100.0)            | 15 (100.0)                 | 113 (92.6)                    |         |       |
| Yes                  | 0 (0.0)               | 0 (0.0)                    | 9 (7.4)                       |         |       |
| Target vessel        |                       |                            |                               | 5.880   | 0.208 |
| LAD                  | 10 (58.8)             | 10 (66.7)                  | 95 (77.9)                     |         |       |
| LCX                  | 2 (11.8)              | 3 (20.0)                   | 6 (4.9)                       |         |       |
| RCA                  | 5 (29.4)              | 3 (13.3)                   | 21 (17.2)                     |         |       |
| Lesion length        | 8.45±4.07             | 10.29±3.92                 | 9.64±3.39                     | 1.204   | 0.303 |
| Location of target plaque |                 |                            |                               | 0.804   | 1.000 |
| Pro                  | 11 (64.7)             | 10 (66.7)                  | 80 (65.6)                     |         |       |
| Mid                  | 6 (35.3)              | 5 (33.3)                   | 40 (32.8)                     |         |       |
| Distal               | 0 (0.0)               | 0 (0.0)                    | 2 (1.6)                       |         |       |

Values are presented as n (%), or mean ± SD; ACS-IFC: Acute Coronary Syndrome with Intact Fibrous Cap; FCT, fibrous cap thickness; MLA, minimal lumen area; NLA, normal lumen area; Pro, proximal.
Table 3: Predictors of the presence of plaque vulnerability as detected by ruptured plaque or nonrupture with TCFA: results of multivariate logistic regression analysis.

| Independent variable | Model 1 |  | Model 2 |  |
|----------------------|---------|---------|---------|---------|
|                      | P       | OR      | 95% CI  | P       | OR      | 95% CI  |
| Diabetes mellitus    | 0.036   | 4.703   | 1.106-19.989 | 0.022   | 4.450   | 1.242-15.939 |
| Male                 | 0.188   | 0.246   | 0.031-1.982 | 0.197   | 0.345   | 0.068-1.740 |
| Current smoking      | 0.775   | 0.804   | 0.181-3.568 | 0.997   | 0.997   | 0.270-3.691 |
| BMI                  | 0.001   | 1.572   | 1.213-2.036 | 0.117   | 1.181   | 0.959-1.454 |
| ACS                  | 0.037   | 4.418   | 1.903-17.847 | 0.047   | 3.498   | 1.017-12.026 |

OR, odds ratio; CI, confidence interval.

Table 4: Fibrinogen levels in patients with different characteristics.

|                      | Group | Fibrinogen       | t/χ² | P   |
|----------------------|-------|------------------|------|-----|
| Gender               | Female| 3.6±1.12         | 1.436| 0.153|
|                      | Male  | 3.4±0.54         |      |     |
| Age                  | <65y  | 3.56±1.04        | 0.104| 0.917|
|                      | ≥65y  | 3.54±0.79        |      |     |
| Hypertension         | No    | 3.58±1.04        | 0.297| 0.767|
|                      | Yes   | 3.53±0.91        |      |     |
| Diabetes mellitus    | No    | 3.56±1.06        | 0.300| 0.764|
|                      | Yes   | 3.51±0.69        |      |     |
| Current smoking      | No    | 3.47±0.93        | 1.164| 0.246|
|                      | Yes   | 3.65±1.01        |      |     |
| Current drinking     | No    | 3.49±0.89        | 1.569| 0.119|
|                      | Yes   | 3.79±1.22        |      |     |
| Family history of CAD| No   | 3.49±0.92        | 1.553| 0.122|
|                      | Yes   | 3.80±1.16        |      |     |
| BMI                  | <24   | 3.53±1.07        | 0.033| 0.968|
|                      | 24-28 | 3.57±1.05        |      |     |
|                      | ≥28   | 3.54±0.64        |      |     |
| HDL-c (mmol/l)       | <1mmol/L| 3.49±0.81      | 0.756| 0.451|
|                      | ≥1mmol/L| 3.61±1.11      |      |     |
| LDL-c (mmol/l)       | <3.1mmol/L| 3.48±0.85    | 1.374| 0.172|
|                      | ≥3.1mmol/L| 3.76±1.32    |      |     |
| T C (mmol/l)         | <5.2mmol/L| 3.50±0.85      | 0.786| 0.448|
|                      | ≥5.2mmol/L| 3.91±1.79      |      |     |
| TG (mmol/l)          | <2.3mmol/L| 3.58±1.05      | 0.823| 0.412|
|                      | ≥2.3mmol/L| 3.43±0.70      |      |     |
| Lp(a) (g/L)          | <300mg/L| 3.51±1.04      | 0.424| 0.672|
|                      | ≥300mg/L| 3.59±0.76      |      |     |
| Clinical diagnosis   | SAP   | 3.54±0.92       | 0.344| 0.709|
|                      | UAP   | 3.63±1.15       |      |     |
|                      | NSTEMI| 3.42±0.83       |      |     |
| Aspirin              | Yes   | 3.75±1.15       | 1.397| 0.165|
|                      | No    | 3.49±0.90       |      |     |
| Statins              | Yes   | 3.72±1.09       | 1.310| 0.192|
|                      | No    | 3.49±0.92       |      |     |
| β-Blockers           | Yes   | 3.66±1.07       | 1.882| 0.062|
|                      | No    | 3.36±0.75       |      |     |

Abbreviations are the same as in Table 1.
# Table 5: Coronary angiographic findings and OCT analysis in patients according to serum fibrinogen levels.

| Group          | Fibrinogen <4.0 | Fibrinogen >4.0 | t/x² | P   |
|----------------|-----------------|-----------------|------|-----|
| PCT(μm)       | 140 (60,230)    | 110 (30,200)    | 1.055| 0.291|
| Lipid arc, degree | 116 (0,174)    | 107 (0,178)    | 0.008| 0.994|
| Rupture (%)   |                 |                 |      |      |
| No            | 117 (90.0)      | 20 (83.3)       | 0.364| 0.546|
| Yes           | 13 (10.0)       | 4 (16.7)        |      |      |
| ACS-IFC (%)   |                 |                 |      |      |
| No            | 116 (89.2)      | 18 (75.0)       | 2.481| 0.115|
| Yes           | 14 (10.8)       | 6 (25.0)        |      |      |
| Macrophage accumulation | 2  | 20 (15.4)  | 7 (29.2) | 4.744 | 0.303 |
|               | 3  | 2 (1.5)    | 0 (0.0)    |      |      |
|               | 4  | 1 (0.8)    | 0 (0.0)    |      |      |
| Vasa vasorum  |                 |                 |      |      |
| No            | 117 (90.0)      | 22 (91.7)       | 0.000| 1.000|
| Yes           | 13 (10.0)       | 2 (8.3)         |      |      |
| Thrombus      |                 |                 |      |      |
| No            | 104 (80.0)      | 17 (70.8)       | 1.011| 0.315|
| Yes           | 26 (20.0)       | 7 (29.2)        |      |      |
| Diameter stenosis, % | 74.43±17.17 | 72.29±14.74 | 0.572 | 0.568 |
| Calcified nodule | No  | 123 (94.6)  | 22 (91.7) | 0.009 | 0.926 |
|                | Yes | 7 (5.4)     | 2 (8.3)     |      |      |
| TCFA          | 25 (19.2)       | 5 (20.8)        | 0.000| 1.000|
| Minimal lumen area (mm²) | 3.57±2.03 | 2.92±1.46 | 1.511 | 0.133 |
| Normal lumen area (mm²) | 10.60±3.13 | 9.90±3.30 | 1.000 | 0.319 |
| Lesion Length | 9.74±3.61       | 8.64±2.90       | 1.413| 0.160|
| Characteristic of plaque | Lipid | 84 (64.6) | 15 (62.5) | 0.042 | 0.979 |
|                | Calcified      | 20 (15.4)       | 4 (16.7)|      |      |
|                | Fibrotic       | 26 (20.0)       | 5 (20.8)|      |      |
|                | LAD, n (%)     | 98 (75.4)       | 17 (70.8)|      |      |
| Target vessel | LCX, n (%)     | 7 (5.4)         | 4 (16.7)| 3.436 | 0.179 |
|                | RCA, n (%)     | 25 (19.2)       | 3 (12.5)|      |      |
|                | Proximal       | 89 (68.5)       | 12 (50.0)|      |      |
| Location of target plaque | Mid  | 39 (30.0) | 12 (50.0) | 3.590 | 0.155 |
|                | Distal         | 2 (1.5)         | 0 (0.0) |      |      |

Abbreviations are the same as in Table 2.
plaque vulnerability [34–39], the current findings in CHD patients did not support a significant effect of fibrinogen on coronary vulnerability, which may reflect the complexity of the pathogenesis of plaque rupture.

4.2. Diabetes and Coronary Atherosclerotic Plaque Vulnerability. Type 2 diabetes has been established as one of the most important risk factors for CHD [40]. Diabetic patients have greater macrophage infiltration and large necrotic cores in their coronary lesions compared to those without diabetes, which confers an increased risk for acute coronary events [41]. However, previous findings on diabetes and coronary vulnerability were mostly derived from experimental studies. Related studies in CHD patients using OCT to evaluate coronary vulnerability have been rarely reported. Here, we showed that diabetes is independently associated with OCT confirmed coronary vulnerability as presented by TCFA and plaque rupture, which is consistent with previous pathology studies. Moreover, this is consistent with a recent study that showed that high glycemic variability was associated with increased OCT-detected plaque vulnerability in nonculprit lesions [42]. After correcting for other confounders, such as ACS, our results support previous OCT studies demonstrating the differences in TCFA prevalence at the culprit lesion [43–45]. Taken together, these findings imply that diabetes leads to pan-coronary vulnerability and contributes to worse prognosis in CHD patients with diabetes.

4.3. Obesity and Coronary Atherosclerotic Plaque Vulnerability. Obesity is recognized as a traditional risk factor for CHD. An early IVUS study showed that obese patient had larger plaque area and higher risk of plaque rupture compared to nonobese patients [46]. Moreover, the amount of visceral adipose tissue was associated with the amount of noncalcified plaques, as demonstrated using computed tomography (CT)-coronary angiography [47]. However, few studies have investigated the potential association between obesity and coronary atherosclerotic plaque vulnerability, particularly via OCT. In our study, higher BMI was independently associated with plaque rupture, but not TCFA, as determined by OCT. This finding is inconsistent with a previous study, which showed that obesity was significantly correlated with TCFA detected by OCT [43]. These inconsistencies may be explained by different patient characteristics. Collectively, these findings highlight the importance of weight loss in preventing cardiovascular adverse events.

4.4. Study Limitations. Our study has limitations that should be taken into consideration when interpreting the results. First, this was a retrospective observational study, and causative associations between diabetes, obesity, and coronary vulnerability could not be derived based on the results. Secondly, we did not include patients with STEMI, and therefore the association between diabetes, obesity, and coronary vulnerability should be evaluated in future studies. Thirdly, we only analyzed plaque composition at the site of target lesions; thus, the association between diabetes, obesity, and coronary vulnerability in nontarget lesions should also be determined in future studies. Finally, a lack of longitudinal follow-up data prohibited assessment of the clinical impact of OCT analysis on future events.

5. Conclusions

Serum fibrinogen was not associated with coronary vulnerability in our cohort, but diabetes, higher BMI, and ACS were independently associated with coronary vulnerability as detected by OCT.

Data Availability

We collected the demographic data, clinical characteristics, risk factors, blood samples, biochemical data, data of ECG, echocardiography, coronary angiography, and optical coherence tomography images in the First Affiliated Hospital of Xinjiang Medical University from January 2015 to August 2018. The data that support the findings of this study are available from the First Affiliated Hospital of Xinjiang Medical University; however, the need for informed consent from eligible patients was waived by the ethics committee.

Ethical Approval

The study protocol was approved by the ethics committee of the First Affiliated Hospital of Xinjiang Medical University. Because of the retrospective design of the study, the need to obtain informed consent from eligible patients was waived by the ethics committee.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Jun Wang and Lu Jia contributed to the work equally and should be regarded as co-first authors.

Acknowledgments

This work was supported by a project grant from Science and Technology Program of Xinjiang Uygur Autonomous Region, China (No. 2016E02072) and project grants of the Research on Prevention and Control of Major Chronic Non-communicable Diseases of China (No. 2018YFC1312804). This study was also supported by research grants from the First Affiliated Hospital of Xinjiang Medical University to Dr. Yang Yining. The authors are thankful that the abstract submitted was accepted by the Academic Committee of the CIT 2019 Conference.

References

[1] U. N. Khot, M. B. Khot, C. T. Bajzer et al., "Prevalence of conventional risk factors in patients with coronary heart
disease,” *Journal of the American Medical Association*, vol. 290, no. 7, pp. 898–904, 2003.

[2] P. Greenland, M. D. Knoll, J. Stamler et al., “Major risk factors as antecedents of fatal and nonfatal coronary heart disease events,” *Journal of the American Medical Association*, vol. 290, no. 7, pp. 891–897, 2003.

[3] T. J. Anderson, J. Grégoire, G. J. Pearson et al., “2016 canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult,” *Canadian Journal of Cardiology*, vol. 32, no. 11, pp. 1263–1282, 2016.

[4] “China overweight obesity medical nutrition treatment expert consensus compilation committee. China overweight/obesity medical nutrition treatment expert consensus(The 2016 edition),” *Chinese Journal Diabetes Mellitus*, vol. 8, no. 10, pp. 525–540, 2016.

[5] World Health Organization study group, diabetes mellitus, World Health Organization Technical Report Series 727: 1-104, 1985.

[6] I. K. Jang, G. J. Teamey, B. MacNeill et al., “In vivo characterization of coronary atherosclerotic plaque by use of optical coherence tomography,” *Circulation*, vol. 111, no. 12, pp. 551–555, 2005.

[7] J. Haibo, A. Farhad, D. Aguirre Aaron et al., “In vivo diagnosis of plaque erosion and calcified nodule in patients with acute coronary syndrome by intravascular optical coherence tomography,” *Journal of the American College of Cardiology*, vol. 62, no. 19, pp. 1748–1758, 2013.

[8] G. J. Teamney, E. Regar, T. Akasaka et al., “Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation,” *Journal of the American College of Cardiology*, vol. 59, no. 18, pp. 1058–1072, 2012.

[9] Ø. R. Mjelva, G. F. T. Svingen, E. K. R. Pedersen et al., “Fibrinogen and neopterin is associated with future myocardial infarction and total mortality in patients with stable coronary artery disease,” *Thrombosis & Haemostasis*, vol. 118, no. 04, pp. 778–790, 2018.

[10] A. G. Zaman, G. Helft, S. G. Worthley, and J. J. Badimon, “The role of plaque rupture and thrombosis in coronary artery disease,” *Atherosclerosis*, vol. 149, no. 2, pp. 251–266, 2000.

[11] B. Keaney, J. Danesh, S. Parish et al., “Fibrinogen and coronary heart disease: test of causality by mendelian randomization,” *International Journal of Epidemiology*, pp. 935–943, 2006.

[12] M. Chapman John, "From pathophysiology to targeted therapy for atherothrombosis: a role for the combination of statin and aspirin in secondary prevention," *Pharmacology & Therapeutics*, vol. 113, pp. 184–196, 2007.

[13] K. Komukai, T. Kubo, H. Kitabata et al., "Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY-FIT study," *Journal of the American College of Cardiology*, vol. 64, no. 16, pp. 2207–2217, 2014.

[14] M. M. Tabakci, F. Gerin, M. Sunbul et al., “Relation of plasma fibrinogen level with the presence, severity, and complexity of coronary artery disease,” *Clinical and Applied Thrombosis/Hemostasis*, vol. 23, no. 6, pp. 638–644, 2016.
[31] N. Buljubasic, K. M. Akkerhuis, J. M. Cheng et al., “Fibrinogen in relation to degree and composition of coronary plaque on intravascular ultrasound in patients undergoing coronary angiography,” Coronary Artery Disease, vol. 28, no. 1, pp. 23–32, 2017.

[32] M. Sabater-Lleal, J. Huang, D. Chasman, S. Naitza, A. Dehghan, A. D. Johnson et al., “A multi-ethnic meta-analysis of genome-wide association studies in over 100,000 subjects identifies 23 fibrinogen-associated loci but no strong evidence of a causal association between circulating fibrinogen and cardiovascular disease,” Circulation, vol. 128, no. 12, pp. 1310–1324, 2013.

[33] T. Kume, T. Akasaka, T. Kawamoto et al., “Assessment of coronary intima–media thickness by optical coherence tomography: comparison with intravascular ultrasound,” Circulation Journal, vol. 69, no. 8, pp. 903–907, 2005.

[34] W. B. Kannel, P. A. Wolf, W. P. Castelli et al., “Fibrinogen and risk of cardiovascular disease. The framingham study,” Journal of the American Medical Association, vol. 258, no. 9, pp. 1183–1186, 1987.

[35] D. J. Schneider, D. J. Taatjes, D. B. Howard et al., “Increased reactivity of platelets induced by fibrinogen independent of its binding to the IIb-IIIa surface glycoprotein: a potential contributor to cardiovascular risk,” Journal of the American College of Cardiology, vol. 33, no. 1, pp. 261–266, 1999.

[36] Y. L. Ragino, V. A. Baum, Y. V. Polonskaya, S. R. Baum, and Y. P. Nikitin, “Oxidized fibrinogen and its relationship with hemostasis disturbances and endothelial dysfunction during coronary heart disease and myocardial infarction,” Kardiologiya, vol. 49, no. 9, pp. 4–8, 2009.

[37] E. Ernst, “Fibrinogen as a cardiovascular risk factor - Interrelationship with infections and inflammation,” European Heart Journal, vol. 14, (Suppl K), pp. 82–87, 1993.

[38] M. Naito, T. Hayashi, M. Kuzuya, C. Funaki, K. Asai, and F. Kuzuya, “Effects of fibrinogen and fibrin on the migration of vascular smooth muscle cells in vitro,” Atherosclerosis, vol. 83, no. 1, pp. 9–14, 1990.

[39] M. P. de Maat, A. Pietersma, M. Kofflard, W. Sluiter, and C. Kluijft, “Association of plasma fibrinogen levels with coronary artery disease, smoking and inflammatory markers,” Atherosclerosis, vol. 121, no. 2, pp. 185–191, 1996.

[40] S. M. Haffner, S. Lehto, T. Rönnemaa, K. Pyörälä, and M. Laakso, “Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction,” The New England Journal of Medicine, vol. 339, no. 4, pp. 229–234, 1998.

[41] A. P. Burke, F. D. Kolodgie, A. Zieske et al., “Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 7, pp. 1266–1271, 2004.

[42] M. Gohbara, K. Hibi, T. Mitsushashi et al., “Glycemic variability on continuous glucose monitoring system correlates with non-culprit vessel coronary plaque vulnerability in patients with first-episode acute coronary syndrome: optical coherence tomography study,” Circulation Journal, vol. 80, pp. 202–210, 2016.

[43] M. D. Roberta De Rosa, M. D. Mariuca Vasa-Nicotera et al., “Coronary atherosclerotic plaque characteristics and cardiovascular risk factors,” Circulation Journal, vol. 81, pp. 1165–1173, 2017.

[44] M. Fukunaga, K. Fujii, T. Nakata et al., “Multiple complex coronary atherosclerosis in diabetic patients with acute myocardial infarction: a three-vessel optical coherence tomography study,” EuroIntervention, vol. 8, no. 8, pp. 955–961, 2012.

[45] T. Sugiyama, E. Yamamoto, K. Bryniarski et al., “Coronary plaque characteristics in patients with diabetes mellitus who presented with acute coronary syndromes,” Journal of the American Heart Association, vol. 7, no. 14, 2018.

[46] S. Kang, G. S. Mintz, B. Witzenbichler et al., “Effect of obesity on coronary atherosclerosis and outcomes of percutaneous coronary intervention: grayscale and virtual histology intravascular ultrasound substudy of assessment of dual antiplatelet therapy with drug-eluting stents,” Circulation: Cardiovascular Interventions, vol. 8, no. 1, 2015.

[47] N. Ohashi, H. Yamamoto, J. Horiguchi et al., “Association between visceral adipose tissue area and coronary plaque morphology assessed by CT angiography,” JACC: Cardiovascular Imaging, vol. 3, no. 9, pp. 908–917, 2010.